MedTrace Logo

N-acetylcysteine in Alcohol Dependence

NCT00568087 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2020-03-18

Study results available
· View outcomes & findings →

Summary

The present study is designed to find out if N-acetylcysteine works in reducing alcohol drinking and craving.

Conditions

  • Alcoholism

Interventions

DRUG

N-acetylcysteine

Patients will take oral N-acetylcysteine 900 mg/day for 1 week, 1800 mg/day for 1 week, 2700 mg/day for 1 week, and then 3600 mg/day.

DRUG

Placebo

Patients will take oral placebo (identical matching placebo) during the study period.

Sponsors & Collaborators

  • Minnesota Veterans Medical Research and Education Foundation

    collaborator OTHER

  • Minneapolis Veterans Affairs Medical Center

    lead FED

Principal Investigators

  • Gihyun Yoon, MD · Minneapolis Veterans Affairs Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00568087 on ClinicalTrials.gov